2021
Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy
Lo YC, Price C, Blenman K, Patil P, Zhang X, Robert ME. Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy. American Journal Of Clinical Pathology 2021, 156: 214-228. PMID: 33555016, DOI: 10.1093/ajcp/aqaa217.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overColitisFemaleHumansImmune Checkpoint InhibitorsInflammatory Bowel DiseasesMaleMiddle AgedConceptsInflammatory bowel diseaseCD8/FOXP3 ratioBiopsy specimensCPI patientsPD-1CD68 scoreFOXP3 ratioBowel diseasePD-L1Antibody-treated patientsCheckpoint inhibitor colitisPD-L1 groupInitial biopsy specimensPD-L1 expressionImmune cell reactionsColonic biopsy specimensDrug-specific differencesIBD groupCheckpoint inhibitorsChronicity scoreActivity scoreImmune phenotypeTherapeutic responseColitisShared pathophysiology
2020
Immune Checkpoint Inhibitor–Induced Upper Gastrointestinal Tract Inflammation Shows Morphologic Similarities to, but Is Immunologically Distinct From, Helicobacter pylori Gastritis and Celiac Disease
Irshaid L, Robert ME, Zhang X. Immune Checkpoint Inhibitor–Induced Upper Gastrointestinal Tract Inflammation Shows Morphologic Similarities to, but Is Immunologically Distinct From, Helicobacter pylori Gastritis and Celiac Disease. Archives Of Pathology & Laboratory Medicine 2020, 145: 191-200. PMID: 33501492, DOI: 10.5858/arpa.2019-0700-oa.Peer-Reviewed Original ResearchConceptsHelicobacter pylori gastritisUpper gastrointestinal tractCeliac diseasePylori gastritisCPI therapyCD8 ratioDuodenal biopsiesInflammatory changesLymphoid aggregatesGastrointestinal tractAnti-programmed death receptor-1/Anti-cytotoxic T-lymphocyteDeath receptor-1/Immune checkpoint inhibitor therapyImmune-related adverse eventsDeath ligand 1 antibodyColonic mucosal changesGastrointestinal tract inflammationLamina propria CD3Lamina propria inflammationUpper gastrointestinal biopsiesUpper gastrointestinal injuryCheckpoint inhibitor therapyH pylori gastritisCD8 T cellsPathologic Manifestations of Gastrointestinal and Hepatobiliary Injury in Immune Checkpoint Inhibitor Therapy
Patil PA, Zhang X. Pathologic Manifestations of Gastrointestinal and Hepatobiliary Injury in Immune Checkpoint Inhibitor Therapy. Archives Of Pathology & Laboratory Medicine 2020, 145: 571-582. PMID: 32338534, DOI: 10.5858/arpa.2020-0070-ra.Peer-Reviewed Original ResearchMeSH KeywordsDiagnosis, DifferentialDigestive SystemDigestive System DiseasesHumansImmune Checkpoint InhibitorsInflammationConceptsHepatobiliary injuryCheckpoint inhibitorsCPI therapyActive colitisPathologic manifestationsCytotoxic T-lymphocyte-associated protein 4 inhibitorsT-lymphocyte-associated protein 4 inhibitorsImmune checkpoint inhibitor therapyDeath ligand 1 (PD-L1) inhibitorsAdverse effectsChronic active colitisAdministration of steroidsCheckpoint inhibitor therapyDeath receptor-1Immune checkpoint inhibitorsBile duct injuryChronic active gastritisLigand 1 inhibitorsNodular regenerative hyperplasiaSecondary sclerosing cholangitisDifferential diagnostic considerationsProtein 4 inhibitorsSeverity of injuryIschemic colitisPanlobular hepatitis